The changes were made due to rapid advancement in Barrett’s esophagus treatment. The new guideline recommends:
1. Expanded methods for close BE mucosa infection to decide on endoscopic therapy.
2. Treatment recommendations now include expanded endoscopic ablative therapy use, including patients with low-grade dysplasia.
3. The ACG guidelines recommend against endoscopic ablative therapies for nondysplastic BE patients without dysplasia on EMR with endoscopic surveillance every three to five years.
4. Follow EMR with endoscopic ablative therapy in patients with LGD or high-grade dysplasia with completed resected lesions.
5. All clinicians who are practicing endoscopic ablative procedures offer EMR.
6. There are some earlier diagnostic and monitoring recommendations reduced, including women with GERD are not candidates for routine screening without multiple risk factors.
More articles on gastroenterology:
7 ways 2016 CMS payment updates affect gastroenterology
3 quick facts on EndoGastric Solutions’ new CFO Michael Burke
CMS cuts to colonoscopy reimbursement finalized: 3 things to know
